BeyondSpring Inc.BYSI

BeyondSpring Pharmaceuticals Inc. markets Plinabulin as an immune-activating small molecule with the potential to enhance anti-tumour responses across multiple oncology indications, most recently highlighted in poster presentations at the 2026 ASCO Annual Meeting and in analyses from NACLC 2025. The company’s product page and press releases lean on GEF‑H1-mediated dendritic cell activation and durable clinical benefits to paint a picture of a biotech on the rise, complete with pipeline graphics and conference imagery. Yet the same week those slides were circulating, BeyondSpring’s 10‑Q for the quarter ended 31 March 2026 quietly reported a net loss of $2.2 million, flat operating loss, and negative equity of $34.5 million. (source: BYSI SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1677940/000117184326003372/bysi20260331_10q.htm)

In 2021, BeyondSpring signed the Hengrui Collaboration Agreement that handed commercialisation responsibilities for Plinabulin to Hengrui in China, including sales, marketing, and regulatory obligations, while BeyondSpring retained a services role at the manufacturing level. The agreement also left BeyondSpring eligible for up to roughly $780,000 in pre-clinical, clinical, and regulatory milestone payments plus commercial milestones and royalties tied to net sales-yet the 10‑Q admits no product revenue was booked in the latest quarter. Instead, the company’s cash position sits at $4.0 million, short-term investments at $3.8 million, and operating cash burn at $3.3 million for the period. (source: BYSI SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1677940/000117184326003372/bysi20260331_10q.htm)

BeyondSpring’s latest SEC filings include a 10‑Q for 31 March 2026 showing assets of $18.4 million against liabilities of $48.8 million, zero capital expenditure, $1.1 million of R&D spend, and diluted EPS of -$0.03 for the year to 30 September 2025. Ownership updates filed on 6 July 2026 include Forms BYSI 3 and BYSI 4 that disclose routine equity grants, while the SEC submissions JSON shows a flurry of 8‑K and 8‑K/A filings through late June and early July 2026-most of them procedural rather than transformational. The contrast between the polished product narrative and the thin financial reality is hard to miss: the clinical story is alive and well on conference circuits, but the balance sheet is closer to survival mode. (source: BYSI SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1677940; BYSI SEC submissions JSON, https://data.sec.gov/submissions/CIK0001677940.json)

The company’s official outlets list ASCO 2026 posters and Phase 2 updates as evidence of progress, while the filing record shows a company that has outsourced its revenue engine to a partner, outsourced its manufacturing services, and is now chiefly reliant on contingent payments that have not yet materialised. BeyondSpring’s product page highlights the investigational small molecule’s mechanism and potential, and its newsroom curates conference outputs and clinical updates; but none of that changes the fact that the group’s latest 10‑Q reports negative equity, operating losses, and shrinking liquidity, while its diluted EPS remains in the red. (source: Plinabulin Therapy in Cancer Therapy and Immune Support, https://beyondspringpharma.com/product/; Latest Press Releases Posts - BeyondSpring, https://beyondspringpharma.com/category/press-releases/; Latest News & Media - BeyondSpring, https://beyondspringpharma.com/news/)

If you want the clinical angle, the BeyondSpring pipeline page is the place to visit, where the group maps out late-stage trials, investigator-initiated studies, and early assets across oncology and immunology. If you want the financial angle, the SEC filings are the only source that matters: they show a company still spending on R&D, still waiting on contingent payments, and still reporting negative equity, all while the product narrative continues its promotional tour. The tension between the two stories is the entire story: the filings are the receipts, the conferences are the slides, and the gap between them is written in red ink. (source: BeyondSpring Pharmaceuticals - Pipeline Overview, https://beyondspringpharma.com/pipeline/; BYSI SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001677940.json)

BeyondSpring’s SEC filings remain the primary and only reliable source for numbers, ownership changes, and material events. The group’s product pages and press releases are useful for understanding the clinical narrative, but they do not disclose revenue, cash generation, or earnings-because the filings show they do not yet exist. Until those contingent payments from Hengrui materialise or a new revenue stream appears, the only consistent data points are the ones that arrive via EDGAR. (source: BYSI SEC EDGAR companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001677940.json; BYSI SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1677940)